®
Have you considered a quick and simple opportunity to reduce your respiratory prescribing budget ? Consider NACSYS ® instead of carbocisteine as your first-choice mucolytic in COPD patients .
Oral mucolytics may present a medicines optimisation opportunity , benefitting patients and the local prescribing budget .
More than fifty-seven Medicines Management Organisations across the UK have already chosen NACSYS ® as either their only mucolytic option in COPD , or as an alternative first-line choice for carbocisteine 1 .
NACSYS ® used as a first-choice mucolytic could deliver savings to your organisation and the NHS 2
NACSYS ® is a convenient once daily effervescent mucolytic 3
NACSYS ® significantly reduces tablet burden compared to carbocisteine 3
NACSYS ® is simple to use as it requires no dose titration 3
If you would like to know more about these potential efficiency savings for your organisation , please email us at info @ alturix . com scan this QR code to receive a copy of our Budget Impact Model .
Abridged Prescribing Information
Product name : NACSYS 600mg effervescent tablets .
Composition : Each effervescent tablet contains 600mg of acetylcysteine and sodium hydrogen bicarbonate ( E500 ) which is equivalent to 115mg of sodium .
Therapeutic Indication : NACSYS is indicated for use as a mucolytic in adults with respiratory disorders .
Posology : One effervescent tablet of 600mg to be taken once daily .
Method of Administration : Dissolve NACSYS 600mg effervescent tablets in half a glass of water to produce a solution that can be consumed immediately . Patients with a reduced cough reflex ( elderly and weakened patients ) are advised to take the tablet in the morning .
Contraindications : Hypersensitivity to acetylcysteine or to any of the excipients . The tablets should not be used by children under two years of age .
Special warnings and precautions : Bronchospasm may occur with the use of NACSYS . Treatment with NACSYS should be discontinued immediately if this occurs . The administration of NACSYS may liquefy bronchial secretions and increase their volume . If the patient is unable to expectorate efficiently , postural drainage and bronchoaspiration should be used .
Interactions : Antitussive drugs and acetylcysteine should not be administered concomitantly . Activated charcoal may reduce the effect of acetylcysteine . It is precautionary to advise against the administration of oral antibiotics for at least two hours before or after acetylcysteine . Concurrent administration of acetylcysteine with nitroglycerine may enhance its vasodilatory effect . Acetylcysteine can interfere with the colorimetric assay for the determination of salicylates .
Pregnancy & Lactation : If necessary , NACSYS 600mg may be used during pregnancy and lactation although there are limited data about its use .
Undesirable effects : Common (> 1 / 100 ) undesirable effects have not been reported . Uncommon ( ≥1 / 1000 < 1 / 100 ) Hypersensitivity headache ; tinnitus ; tachycardia ; hypotension , gastrointestinal reaction ( vomiting , diarrhoea , stomatitis , abdominal pain , nausea ); fever . Rare (> 1 / 10000 < 1 / 1000 ): dyspepsia ; Very rare (< 1 / 100000 ): anaphylactic shock , anaphylactic reaction , haemorrhage ; serious skin reactions such as Stevens-Johnson syndrome and Lyell ' s syndrome have very rarely been reported in temporal connection with the use of acetylcysteine . Prescribers should consult the Summary of Product Characteristics in relation to other adverse effects .
Reporting adverse effects : Adverse events should be reported . Reporting forms and information can be found at https :// yellowcard . mhra . gov . uk or search for MHRA Yellow Card in the Google Play or Apple App Store . Adverse events should also be reported to Alturix Limited at safety @ alturix . com and + 44 ( 0 ) 1908 038 083
NHS price : £ 5.50 for a pack of thirty effervescent tablets . Legal classification : POM
Distributor : Alturix Limited , 287 Upper Fourth Street , Milton Keynes , MK9 1EH , UK
MA number : PL 44490 / 0006 Date of revision of the text : October 2020 Job Code : AL0139
Ref : 1 . Data on file , Discovery online , accessed 28 / 07 / 2021 2 . Data on file , Budget Impact Model , accessed 28 / 07 / 2021 3 . SmPC NACSYS accessed at mhra . gov . uk / spc-pil AL0192 Date of preparation : August 2022